瘦型非酒精性脂肪性肝病的特点及其研究进展

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)是目前最常见的慢性肝脏疾病之一,若不及时干预,可进一步发展为脂肪性肝炎、肝硬化,并出现一系列代谢性疾病。先前的研究都认为NAFLD的发生与肥胖密切相关,然而在瘦型人群中,尤其是在亚洲人群里,同样存在着一部分NAFLD患者。目前的NAFLD患者管理主要是针对肥胖人群,而对瘦型NAFLD患者研究较少,因此这篇文章将从临床特征、发病机制以及治疗等方面分析瘦型NAFLD的特点以及最新研究进展。

林惟妙, 虞朝辉. 瘦型非酒精性脂肪性肝病的特点及其研究进展[J]. 肝脏, 2021, 26(8): 932-935.

参考文献

[1] Fan J-G, Kim S-U, Wong V W-S. New trends on obesity and NAFLD in Asia. Journal of Hepatology, 2017, 67: 862-873.
[2] Wang AY, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease. Clin Nutr, 2019, 38: 975-981.
[3] Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol, 2012, 47: 586-595.
[4] Zou B, Yeo YH, Nguyen VH, et al. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J Intern Med, 2020: 1-13.
[5] Wei JL, Leung J C-F, Loong T C-W, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. American Journal of Gastroenterology, 2015, 110: 1306-1314.
[6] Kwon YM, Oh SW, Hwang SS, et al. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol, 2012, 107: 1852-1858.
[7] Das K, Das K, Mukherjee P S, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology, 2010, 51: 1593-1602.
[8] Niriella MA, Kasturiratne A, Pathmeswaran A, et al. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. Hepatol Int, 2019, 13: 314-322.
[9] Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol, 2009, 44: 471-477.
[10] Succurro E, Marini MA, Frontoni S, et al. Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. Obesity (Silver Spring), 2008, 16: 1881-1886.
[11] Feldman A, Eder SK, Felder TK, et al. Clinical and metabolic characterization of lean caucasian subjects with non-alcoholic fatty liver. American Journal of Gastroenterology, 2017, 112: 102-110.
[12] Leung JC, Loong TC, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology, 2017, 65: 54-64.
[13] Denkmayr L, Feldman A, Stechemesser L, et al. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. Journal of Clinical Medicine, 2018, 7: 1-12.
[14] Bernhardt P, Kratzer W, Schmidberger J, et al. Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis. BMC Res Notes, 2018, 11: 101.
[15] Feng R-N, Du S-S, Wang C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World Journal of Gastroenterology, 2014, 20: 17932-17940.
[16] Fracanzani A L, Petta S, Lombardi R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol, 2017, 15: 1604-1611 e1.
[17] Shao C, Ye J, Li F, et al. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Dig Liver Dis, 2019, 51: 1392-1399.
[18] Hagström H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatology Communications, 2017, 2: 48-57.
[19] Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2009, 136: 1585-1592.
[20] Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia, 2009, 52: 1056-1060.
[21] Musso G, Bo S, Cassader M, et al. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. The American Journal of Clinical Nutrition, 2013, 98: 895-906.
[22] Fan Y, Lu H, Guo Y, et al. Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice. Gastroenterology, 2016, 150: 1208-1218.
[23] Chen F, Esmaili S, Rogers GB, et al. Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. Hepatology, 2020, 71: 1213-1227.
[24] Yamakado M, Tanaka T, Nagao K, et al. Plasma amino acid profile is associated with visceral fat accumulation in obese Japanese subjects. Clin Obes, 2012, 2: 29-40.
[25] Eshraghian A, Nikeghbalian S, Geramizadeh B, et al. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid. Clin Res Hepatol Gastroenterol, 2019: 1-7.
[26] Zhang YN, Wang QQ, Chen YS, et al. Association between serum uric acid to HDL-cholesterol ratio and nonalcoholic fatty liver disease in lean chinese adults. Int J Endocrinol, 2020, 2020: 1-6.
[27] Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology, 2014, 146: 1513-1524.
[28] Yun Y, Kim HN, Lee EJ, et al. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects. PLoS One, 2019, 14: e0213692.
[29] Assy NNG, Kamayse I,et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol, 2008, 22: 811-816.
[30] Alam S, Jahid Hasan M, Khan M A S, et al. Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient. J Transl Int Med, 2019, 7: 106-114.
[31] Kwak MS, Kim D, Chung G E, et al. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. Liver Int, 2015, 35: 944-952.
[32] Hallsworth K, Fattakhova G, Hollingsworth K G, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut, 2011, 60: 1278-1283.
[33] Ipsen DH, Rolin B, Rakipovski G, et al. Liraglutide decreases hepatic inflammation and injury in advanced lean non-alcoholic steatohepatitis. Basic Clin Pharmacol Toxicol, 2018, 123: 704-713.
[34] Enjoji M, Machida K, Kohjima M, et al. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis, 2010, 9: 29.
[35] 谭彦芳,赵彩彦. 非酒精性脂肪肝病药物治疗进展. 实用肝脏病杂志, 2013, 16: 378-381.